Why has Hims and her stock sunk today

Hims & Hers Health (Hims -3.39%))) fell by 5.6% until 12.20 p.m. Bank of America Analysts gave mixed messages this morning on the inventory.

Bofa increased the price target for the shares to 21 USD and confirmed the fly and still repeated an “underperform” (ie Sell) rating for HIMS & HERS share. Investors take the hint and do exactly that.

Why is Bofa worried about Hims & Huse?

HIMS & HERS share was a mega outperformer for investors who grows by more than 600% last year, mainly on the back of his compound semaglutid products that have the effect of Ozempic and similar weight loss medication of large pharmaceutical companies such as imitation Novo Nordisk And Eli Lilly. But the opportunity that turned out to be Novo and Lilly were unable to satisfy the demand for GLP-1 products, also has a risk for the stock, Bofa reports.

On the one hand, the banker sees “Wahl” on the sales estimates for the fourth quarter of IMS & HUL. Bofa also predicts that the instructions of Q1 2025 will be “sensible” to the expectations of the analysts – that HIMS & BE will lead to an income strike.

The problem is how Hims & you let her happen.

Bofa estimates that sales with GLP-1 in the second quarter of 2025 could make up more than 50% of the sales of HIMS & HERS, which overweight the company’s trust in just one product for half of its business. Since it is only a matter of time until Novo and Lilly have sunk enough that there is no need for compounders such as HIMS and Heis to compensate for the deficit of the GLP-1 offer, and this business disappears, Bofa will soon forecast sales From a cliff.

Is Hims & Huger a sale?

But here is the curious thing: Most analysts of Wall Street see that HIMS & HERS sales continue to grow in size by 2027 and is indeed the size of the size in size, Times income is three years away.

This is a pretty high price. I agree with Bofa that he makes him a sale.